MRX-4

Summary

Mrx-4 (CHEMBL4301914) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 1
• Chemistry: 530.3 Da · C20H18F3N4O8P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4301914
Name	MRX-4
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	91864617
Molecular formula	C20H18F3N4O8P
Molecular weight	530.3
InChIKey	YCRAGJLWFBGKFE-CYBMUJFWSA-N

SMILES: CC(=O)OP(=O)(N(C[C@H]1CN(C(=O)O1)C2=CC(=C(C(=C2F)F)N3CCC(=O)C=C3)F)C4=NOC=C4)O

IUPAC name: acetyloxy-N-(1,2-oxazol-3-yl)-N-[[(5R)-2-oxo-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]phosphonamidic acid

Also known as: Mrx-4, Prodrug of contezolid (mrx-1)

Parent form; salt/anhydrous children: CHEMBL3989966

Patent coverage: 4 distinct patent families (12 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8 (67%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03033329	PHASE1	COMPLETED	Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).